Abstract: Dasatinib was identified to be associated with pulmonary arterial hypertension, also called dasatinib-induced pulmonary arterial hypertension. There was still little data on clinical characteristics of this rare but severe complication during hematological therapy in China. A 40-year-old female with worsening dyspnoea was diagnosed with severe pulmonary arterial hypertension and progressive right heart failure, and stabilized by standardized comprehensive management, including replacement of other tyrosine kinase inhibitor, administration of pulmonary vasodilators according to the right-heart catheterization-based risk stratification and traditional anti-heart failure drug therapy. Our case suggests that dasatinib-induced pulmonary arterial hypertension may be partially reversible, with a relatively good prognosis under formal target therapy of pulmonary arterial hypertension, providing new insight into its treatment algorithm.
Keywords: dasatinib-induced pulmonary arterial hypertension, right heart failure, pulmonary vasodilator, tyrosine kinase inhibitor